Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + anti-prostate-specific membrane antigen antibody
- Development stage
- Unknown
- Lead developer
- Weill Cornell Medicine
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of the taxane chemotherapeutic agent docetaxel and an anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (such as J591). Docetaxel acts as a microtubule stabilizer, promoting tubulin polymerization and inhibiting microtubule depolymerization, which leads to cell cycle arrest at the G2/M phase and subsequent apoptosis. The anti-PSMA antibody specifically targets the extracellular domain of PSMA, a type II transmembrane glycoprotein highly overexpressed in prostate cancer cells. When combined, the anti-PSMA antibody can be used to deliver targeted cytotoxic effects or radiosensitizing properties (when radiolabeled, such as with Lutetium-177 or Actinium-225) in synergy with docetaxel chemotherapy to treat advanced prostate cancer.
- Other names
- docetaxel + anti-PSMA antibodydocetaxel + anti-prostate-specific membrane antigen monoclonal antibodydocetaxel + J591
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on docetaxel + anti-prostate-specific membrane antigen antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + anti-prostate-specific membrane antigen antibody.